Accessibility Menu
bioAffinity Technologies logo

bioAffinity Technologies(NASDAQ) BIAF

Market Cap$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-95%
1 Month-44%
$0.40
-0.05%
-0.00Today
bioAffinity Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.402026-08-14
bioAffinity Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.16%USD 0.512026-08-07
1 month-44.34%USD 0.722026-07-15
3 month-78.61%USD 1.882026-05-15
Year to date-65.92%USD 1.182025-12-31
1 year-94.75%USD 7.662025-08-14
3 year-99.28%USD 55.652023-08-15
Since inception-99.84%USD 249.002022-09-01

bioAffinity Technologies Financials at a Glance

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.90M

Net Income (TTM)

-$15.19M

EPS (TTM)

-$6.89

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$0.40

Volume

254,726.41

Open

$0.42

Previous Close

$0.40

Daily Range

$0.39 - $0.42

52-Week Range

$0.33 - $13.50

Estimated Earnings Date

Nov 18, 2026

BIAF News

Foolcom-Featured.png

bioAffinity Misses Q2 Revenue Target

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About bioAffinity Technologies

bioAffinity Technologies helps doctors find lung cancer early with a simple test. Its main product, CyPath Lung, uses a home-collected sample to spot cancer risk. The company also researches new ways to treat cancer at the cell level.

Products and Services

  • CyPath Lung (15.6% of 2025 revenue): Noninvasive lung cancer test using sputum samples, aimed at early detection for high-risk patients.
  • Laboratory Services (approximately 99.9% of 2025 revenue): Clinical pathology and histology services for physicians, including patient and medical director fees.
  • Asthma/COPD Diagnostics (in development): Tests to measure lung inflammation and identify treatment targets for asthma and chronic obstructive pulmonary disease.
  • Cancer Therapeutics Research: Early-stage research on targeted therapies, including treatments for skin and other cancers.

Growth and Expansion

  • Launched CyPath Lung commercially and expanded sales team in 2025.
  • Entered the Mid-Atlantic US market in 2025 to broaden test access.
  • Started a multi-site clinical trial for CyPath Lung in March 2026, supported by the John P. Murtha Cancer Center Research Program.
  • Collaborated with military medical centers for clinical validation and new diagnostic development.
  • Discontinued unprofitable pathology services in 2025 to focus on core diagnostics.

What Makes bioAffinity Special

The company’s main test uses a home-collected sample, making cancer screening less invasive. Its technology combines machine learning and flow cytometry, which helps standardize results and reduce human error. A strong patent portfolio and partnerships with research centers support its competitive position.

Five Things You Need to Know

  • Revenue was $6.2 million in 2025, down 34% from 2024.
  • CyPath Lung test revenue rose 87% in 2025, reaching $963,000.
  • Net loss was $14.9 million in 2025, compared to $9.0 million in 2024.
  • Cash and cash equivalents were $6.4 million at year-end 2025.

Bottom Line

bioAffinity has shifted focus to its core diagnostic test and research, streamlining operations. The company faces ongoing financial challenges but continues to develop new cancer detection and treatment tools.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

57

CEO

Maria Zannes

Website

www.bioaffinitytech.com

Headquarters

San Antonio, TX 78217, US

BIAF Financials

Key Financial Metrics (TTM)

Gross Margin

-39.57%

Operating Margin

-209.82%

Net Income Margin

-257.33%

Return on Equity

-257.27%

Return on Capital

-125.29%

Return on Assets

-199.30%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.10M

Volume

254.73K

Avg. Volume

394.33K

Financials (TTM)

Gross Profit

-$2.33M

Operating Income

-$12.38M

EBITDA

-$14.72M

Operating Cash Flow

-$11.47M

Capital Expenditure

-$31.41K

Free Cash Flow

-$11.50M

Cash & ST Invst.

$2.43M

Total Debt

$1.44M

bioAffinity Technologies Performance Analysis

bioAffinity Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,803N/A
20232023-12-31USD 2,532,49952627.4%
20242024-12-31USD 9,362,022269.7%
20252025-12-31USD 6,161,959-34.2%
bioAffinity Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.9%
Q42025-12-3110.1%
Q12026-03-31-15.1%
Q22026-06-3011.8%
bioAffinity Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -54.37111.4%
20232023-12-31USD -27.22-49.9%
20242024-12-31USD -22.37-17.8%
20252025-12-31USD -8.66-61.3%
bioAffinity Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.5%
Q42025-12-3161.6%
Q12026-03-3155.5%
Q22026-06-3021.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.51M

+19.0%

Gross Profit

-$3.33M

-1418.7%

Gross Margin

-2.21%

N/A

Market Cap

$3.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$57.15K

N/A

Employees

57

N/A

Net Income

-$3.37M

+17.1%

EBITDA

-$3.29M

+15.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.43M

+202.6%

Total Debt

$1.44M

+114.2%

Accounts Receivable

$894.82K

+112.1%

Inventory

$82.38K

+87.3%

Long Term Debt

$1.17M

+261.0%

Short Term Debt

$265.43K

-23.3%

Return on Assets

-1.99%

N/A

Return on Invested Capital

-2.51%

N/A

Free Cash Flow

-$3.29M

-23.7%

Operating Cash Flow

-$3.20M

-20.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTLArtelo Biosciences, Inc.
$0.72-9.38%
REVBRevelation Biosciences, Inc.
$1.13+7.25%
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
WOKWORK Medical Technology Group Ltd. Class A
$2.44+9.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
IPSTIp Strategy
$8.04+2.65%
SPCXSpace Exploration Technologies
$148.75+0.06%
NOKNokia
$10.98+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.65-0.01%

Questions About BIAF

What is the current price of bioAffinity Technologies?

bioAffinity Technologies is trading at $0.40 per share.

What is the 52-week range for bioAffinity Technologies?

Over the past 52 weeks, bioAffinity Technologies has traded between $0.33 and $13.50.

How much debt does bioAffinity Technologies have?

As of the most recent reporting period, bioAffinity Technologies reported total debt of $1.44M.

How much cash does bioAffinity Technologies have on hand?

bioAffinity Technologies reported $2.43M in cash and cash equivalents in its most recent financial results.

What is bioAffinity Technologies’s dividend yield?

bioAffinity Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services